Cyclacel Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CYCC)

$1.54 -0.02 (-1.28 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$1.54
Today's Range$1.50 - $1.61
52-Week Range$1.47 - $10.90
Volume116,090 shs
Average Volume267,807 shs
Market Capitalization$18.14 million
P/E Ratio-0.63
Dividend YieldN/A
Beta3.74

About Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Receive CYCC News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CYCC
CUSIPN/A
Phone+1-908-5177330

Debt

Debt-to-Equity RatioN/A
Current Ratio6.53%
Quick Ratio6.53%

Price-To-Earnings

Trailing P/E Ratio-0.626016260162602
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$840,000.00
Price / Sales21.82
Cash FlowN/A
Price / CashN/A
Book Value$3.36 per share
Price / Book0.46

Profitability

Trailing EPS($2.46)
Net Income$-11,790,000.00
Net MarginsN/A
Return on Equity-54.66%
Return on Assets-42.12%

Miscellaneous

Employees13
Outstanding Shares11,900,000

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals shares reverse split on the morning of Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) posted its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter. View Cyclacel Pharmaceuticals' Earnings History.

Who are some of Cyclacel Pharmaceuticals' key competitors?

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the folowing people:

  • David Charles U'Prichard Ph.D., Independent Chairman of the Board (Age 68)
  • Spiro George Rombotis, President, Chief Executive Officer, Director (Age 57)
  • Christopher S. Henney Ph.D., Independent Vice Chairman of the Board (Age 76)
  • Paul McBarron, Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director (Age 55)
  • Judy H. Chiao M.D., Vice President - Clinical Development and Regulatory Affairs (Age 56)
  • John Michael Middlecott Banham, Independent Director (Age 77)
  • Samuel L. Barker Ph.D., Independent Director (Age 74)
  • Gregory T. Hradsky, Independent Director (Age 55)
  • Lloyd M. Sems, Independent Director (Age 45)

Who owns Cyclacel Pharmaceuticals stock?

Cyclacel Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Virtu Financial LLC (1.68%), Two Sigma Investments LP (0.59%) and Citadel Advisors LLC (0.52%). Company insiders that own Cyclacel Pharmaceuticals stock include Eastern Capital Ltd and Kevin C Tang. View Institutional Ownership Trends for Cyclacel Pharmaceuticals.

Who bought Cyclacel Pharmaceuticals stock? Who is buying Cyclacel Pharmaceuticals stock?

Cyclacel Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Two Sigma Investments LP and Citadel Advisors LLC. Company insiders that have bought Cyclacel Pharmaceuticals stock in the last two years include Eastern Capital Ltd and Kevin C Tang. View Insider Buying and Selling for Cyclacel Pharmaceuticals.

How do I buy Cyclacel Pharmaceuticals stock?

Shares of Cyclacel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cyclacel Pharmaceuticals' stock price today?

One share of Cyclacel Pharmaceuticals stock can currently be purchased for approximately $1.54.

How big of a company is Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals has a market capitalization of $18.14 million and generates $840,000.00 in revenue each year. The biotechnology company earns $-11,790,000.00 in net income (profit) each year or ($2.46) on an earnings per share basis. Cyclacel Pharmaceuticals employs 13 workers across the globe.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 Connell Dr Ste 1500, BERKELEY HEIGHTS, NJ 07922-2811, United States. The biotechnology company can be reached via phone at +1-908-5177330 or via email at [email protected]


MarketBeat Community Rating for Cyclacel Pharmaceuticals (CYCC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  124
MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Consensus Price Target History

Price Target History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2016HC WainwrightReiterated RatingBuyN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Earnings History and Estimates Chart

Earnings by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cyclacel Pharmaceuticals (NASDAQ CYCC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.91)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.50)ViewListenView Earnings Details
5/11/2017Q1 2017($0.38)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.73)($0.69)$0.21 million$0.28 millionViewN/AView Earnings Details
11/14/2016Q316($0.94)($0.86)$0.42 million$0.21 millionViewN/AView Earnings Details
8/10/2016Q216($1.01)$0.22 millionViewListenView Earnings Details
5/11/2016Q116($0.09)$512.00 million$139.00 millionViewListenView Earnings Details
3/24/2016Q4($0.08)($0.10)$0.51 million$0.42 millionViewListenView Earnings Details
11/12/2015Q315($0.09)($0.08)$0.30 million$0.72 millionViewListenView Earnings Details
8/11/2015Q215($0.10)$0.30 millionViewListenView Earnings Details
5/12/2015Q115($0.25)($0.19)$0.51 millionViewListenView Earnings Details
3/24/2015Q414($0.26)($0.21)$0.25 millionViewN/AView Earnings Details
11/11/2014Q314($0.26)($0.22)$0.74 millionViewN/AView Earnings Details
8/12/2014Q214($0.28)($0.22)$0.36 millionViewN/AView Earnings Details
5/13/2014Q114($0.24)($0.25)$0.40 millionViewN/AView Earnings Details
3/25/2014Q413($0.33)($0.19)$0.09 million$0.30 millionViewN/AView Earnings Details
11/12/2013Q3($0.31)($0.31)$0.31 millionViewListenView Earnings Details
8/14/2013Q2 2013($0.10)$0.03 million$0.26 millionViewN/AView Earnings Details
5/13/2013Q1 2013($1.18)$0.21 millionViewN/AView Earnings Details
3/27/2013Q4 2012($6.60)ViewN/AView Earnings Details
11/12/2012Q312($0.37)ViewN/AView Earnings Details
8/14/2012Q2 2012($6.72)($5.04)ViewN/AView Earnings Details
5/14/2012Q1 2012($6.72)($5.04)ViewN/AView Earnings Details
3/29/2012Q4 2011($6.72)($5.96)ViewN/AView Earnings Details
11/14/2011Q3 2011($6.72)($5.71)ViewN/AView Earnings Details
8/11/2011Q2 2011($9.24)($6.72)ViewN/AView Earnings Details
5/12/2011Q1 2011($7.56)($8.57)ViewN/AView Earnings Details
3/23/2011Q4 2010($8.40)($6.13)ViewN/AView Earnings Details
11/11/2010Q3 2010($12.60)($9.07)ViewN/AView Earnings Details
8/5/2010Q2 2010($14.28)($15.04)ViewN/AView Earnings Details
5/13/2010Q1 2010($12.60)($15.37)ViewN/AView Earnings Details
3/23/2010Q4 2009($14.28)($14.79)ViewN/AView Earnings Details
11/3/2009Q3 2009($18.48)($10.92)ViewN/AView Earnings Details
8/6/2009Q2 2009($21.84)($20.50)ViewN/AView Earnings Details
5/14/2009Q1 2009($25.20)($20.83)ViewN/AView Earnings Details
3/31/2009Q4 2008($27.72)($32.68)ViewN/AView Earnings Details
11/6/2008Q3 2008($36.12)($24.87)ViewN/AView Earnings Details
8/7/2008Q2 2008($31.92)($35.12)ViewN/AView Earnings Details
5/9/2008Q1 2008($32.76)($25.71)ViewN/AView Earnings Details
3/11/2008Q4 2007($34.44)($46.71)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/9/2016Annual$0.157/13/20167/17/20168/1/2016
(Data available from 1/1/2013 forward)

Insider Trades

Cyclacel Pharmaceuticals (NASDAQ CYCC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 10.25%
Insider Trades by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Institutional Ownership by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cyclacel Pharmaceuticals (NASDAQ CYCC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/19/2017Eastern Capital LtdMajor ShareholderBuy850,000$2.00$1,700,000.002,167,261View SEC Filing  
2/23/2017Kevin C TangMajor ShareholderBuy134,200$4.34$582,428.00View SEC Filing  
11/20/2014Sam L BarkerDirectorBuy3,100$3.00$9,300.00View SEC Filing  
5/21/2013Lloyd SemsDirectorBuy33,333$3.00$99,999.00View SEC Filing  
5/21/2013Paul McbarronCFOBuy12,948$3.03$39,232.44View SEC Filing  
5/21/2013Spiro George RombotisInsiderBuy100,000$3.00$300,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cyclacel Pharmaceuticals (NASDAQ CYCC) News Headlines

Source:
DateHeadline
Cyclacel Pharma (CYCC) Announces New European Patent Covering Sapacitabine Pharmaceutical FormulationsCyclacel Pharma (CYCC) Announces New European Patent Covering Sapacitabine Pharmaceutical Formulations
www.streetinsider.com - February 21 at 8:47 AM
Cyclacel Pharmaceuticals (CYCC) Presents At BIO CEO & Investor Conference - SlideshowCyclacel Pharmaceuticals (CYCC) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:59 PM
Cyclacel Pharmaceuticals (CYCC) Presents At Noble Financial Capital Markets 14th Annual Investor Conference - SlideshowCyclacel Pharmaceuticals (CYCC) Presents At Noble Financial Capital Markets 14th Annual Investor Conference - Slideshow
seekingalpha.com - February 11 at 4:17 PM
Should You Be Concerned About Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Shareholders?Should You Be Concerned About Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Shareholders?
finance.yahoo.com - February 6 at 9:34 AM
Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor ConferenceCyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference
feeds.benzinga.com - February 6 at 7:43 AM
Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Earnings Declined -24.93%, But How Did It Fare Against The Industry?Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Earnings Declined -24.93%, But How Did It Fare Against The Industry?
finance.yahoo.com - January 20 at 9:53 AM
Cyclacel Pharma (CYCC) Reviews 2017 Achievements, Announces Key Business Objectives for 2018 - StreetInsider.comCyclacel Pharma (CYCC) Reviews 2017 Achievements, Announces Key Business Objectives for 2018 - StreetInsider.com
www.streetinsider.com - January 9 at 9:47 AM
Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018
finance.yahoo.com - January 9 at 9:47 AM
What You Must Know About Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Financial HealthWhat You Must Know About Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Financial Health
finance.yahoo.com - January 2 at 6:06 PM
Cyclacel (CYCC) Announces Presentation of Results From Phase 3 Seamless Study at ASHCyclacel (CYCC) Announces Presentation of Results From Phase 3 Seamless Study at ASH
www.streetinsider.com - December 13 at 5:12 PM
ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 13, 2017ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 5:12 PM
Cyclacel (CYCC) Announces Presentation of Results From Phase 3 Seamless Study at ASH - StreetInsider.comCyclacel (CYCC) Announces Presentation of Results From Phase 3 Seamless Study at ASH - StreetInsider.com
www.streetinsider.com - December 12 at 10:15 AM
Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual MeetingCyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting
finance.yahoo.com - December 12 at 10:15 AM
ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : November 27, 2017ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 6:06 PM
Cyclacel Pharmaceuticals (CYCC) CEO Spiro Rombotis on Q3 ... - Seeking AlphaCyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 ... - Seeking Alpha
seekingalpha.com - November 10 at 8:41 AM
Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial ResultsCyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 10 at 8:41 AM
Edited Transcript of CYCC earnings conference call or presentation 9-Nov-17 9:30pm GMTEdited Transcript of CYCC earnings conference call or presentation 9-Nov-17 9:30pm GMT
finance.yahoo.com - November 10 at 8:41 AM
Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results - GlobeNewswire (press release)Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 4 at 7:48 PM
Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial ResultsCyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results
feeds.benzinga.com - November 2 at 7:43 AM
Cyclacel Pharmaceuticals (CYCC) Presents At Ladenburg Thalmann 2017 Healthcare Conference - SlideshowCyclacel Pharmaceuticals (CYCC) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 6:49 PM
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference - GlobeNewswire (press release)Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 21 at 5:45 PM
Cyclacel Pharmaceuticals Preferred Stock Shares Cross 10% Yield MarkCyclacel Pharmaceuticals' Preferred Stock Shares Cross 10% Yield Mark
www.thestreet.com - September 19 at 5:44 PM
Short Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Decreases By 35.8%Short Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Decreases By 35.8%
www.americanbankingnews.com - September 17 at 1:20 AM
Todays Research Reports on Trending Tickers: Cyclacel Pharmaceuticals and MannKind CorporationToday's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals and MannKind Corporation
finance.yahoo.com - September 13 at 7:01 PM
Cyclacel Pharmaceuticals (CYCC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowCyclacel Pharmaceuticals (CYCC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 12 at 6:24 PM
Short Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Drops By 23.5%Short Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Drops By 23.5%
www.americanbankingnews.com - August 14 at 2:38 AM
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Issues Quarterly  Earnings ResultsCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 11:04 PM
Edited Transcript of CYCC earnings conference call or presentation 9-Aug-17 8:30pm GMTEdited Transcript of CYCC earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:58 PM
Cyclacel Pharmaceuticals (CYCC) CEO Spiro Rombotis on Q2 2017 Results - Earnings Call Transcript - Seeking AlphaCyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 4:00 AM
Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 5:55 PM
Cyclacel Pharma (CYCC) Reports Selection of Recommended ... - StreetInsider.comCyclacel Pharma (CYCC) Reports Selection of Recommended ... - StreetInsider.com
www.streetinsider.com - August 7 at 11:06 PM
Part 2 of study will focus on cyclin E amplified drug resistant solid tumorsPart 2 of study will focus on cyclin E amplified drug resistant solid tumors
globenewswire.com - August 7 at 6:05 PM
Form 8-K Cyclacel Pharmaceuticals For: Aug 07Form 8-K Cyclacel Pharmaceuticals For: Aug 07
www.streetinsider.com - August 7 at 6:05 PM
Cyclacel Pharmaceuticals to Release Second Quarter 2017 ... - GlobeNewswire (press release)Cyclacel Pharmaceuticals to Release Second Quarter 2017 ... - GlobeNewswire (press release)
globenewswire.com - August 2 at 6:32 PM
Cyclacel Announces Closing of $15.2 Million Underwritten Public ... - GlobeNewswire (press release)Cyclacel Announces Closing of $15.2 Million Underwritten Public ... - GlobeNewswire (press release)
globenewswire.com - July 22 at 12:29 AM
Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option - NasdaqCyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option - Nasdaq
www.nasdaq.com - July 21 at 7:27 PM
Insider Buying: Cyclacel Pharmaceuticals, Inc. (CYCC) Major Shareholder Purchases 850,000 Shares of StockInsider Buying: Cyclacel Pharmaceuticals, Inc. (CYCC) Major Shareholder Purchases 850,000 Shares of Stock
www.americanbankingnews.com - July 21 at 7:10 PM
Todays Research Reports on Trending Tickers: Cyclacel Pharmaceuticals Inc. and Canadian Solar Inc.Today's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals Inc. and Canadian Solar Inc.
finance.yahoo.com - July 20 at 7:45 PM
Cyclacel Announces Pricing of $13.2 Million Underwritten Public OfferingCyclacel Announces Pricing of $13.2 Million Underwritten Public Offering
globenewswire.com - July 19 at 6:53 PM
22 Stocks Moving In Fridays Pre-Market Session - Benzinga22 Stocks Moving In Friday's Pre-Market Session - Benzinga
www.benzinga.com - May 12 at 5:09 PM
Cyclacel Pharmaceuticals (CYCC) CEO Spiro Rombotis on Q1 2017 Results - Earnings Call Transcript - Seeking AlphaCyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 12 at 3:20 AM
Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial ResultsCyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results
feeds.benzinga.com - May 5 at 7:43 AM
BUZZ-U.S. STOCKS ON THE MOVE-Yingli Green, Calix, Hertz Global, Cyclacel Pharma - NasdaqBUZZ-U.S. STOCKS ON THE MOVE-Yingli Green, Calix, Hertz Global, Cyclacel Pharma - Nasdaq
www.nasdaq.com - April 3 at 5:02 PM
Cyclacel Pharmaceuticals Inc. (CYCC) Is Spiking Higher On CYC065 News - RTT NewsCyclacel Pharmaceuticals Inc. (CYCC) Is Spiking Higher On CYC065 News - RTT News
www.rttnews.com - April 3 at 5:02 PM
Cyclacels CYC065 Succeeds in Lung Cancer StudyCyclacel's CYC065 Succeeds in Lung Cancer Study
www.investopedia.com - April 3 at 5:02 PM
After-Hours Earnings Report for March 28, 2017 : PLAY, VRNT, OLLI, SONC, WLB, AST, IZEA, CYCC - NasdaqAfter-Hours Earnings Report for March 28, 2017 : PLAY, VRNT, OLLI, SONC, WLB, AST, IZEA, CYCC - Nasdaq
www.nasdaq.com - March 28 at 4:23 PM
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
biz.yahoo.com - March 28 at 4:23 PM
Q4 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market CloseQ4 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 28 at 12:18 PM
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other EventsCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - March 13 at 4:43 PM
Cyclacel Pharma (CYCC) CDK Inhibitor CYC065 Causes Anaphase Catastrophe Featured in JNCI Publication - StreetInsider.comCyclacel Pharma (CYCC) CDK Inhibitor CYC065 Causes Anaphase Catastrophe Featured in JNCI Publication - StreetInsider.com
www.streetinsider.com - March 9 at 5:11 PM

SEC Filings

Cyclacel Pharmaceuticals (NASDAQ:CYCC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cyclacel Pharmaceuticals (NASDAQ CYCC) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.